{
    "PMC8668943_3": [
        {
            "subject": {
                "HIV-1 acquisition": "reduced odds",
                "Odds Ratio (OR)": "0.29",
                "Confidence Interval (CI)": "0.12-0.71",
                "P-value": "0.007",
                "Bonferroni corrected P-value (PBonf)": "0.112",
                "Dataset": "Perinatal HIV-1 acquisition",
                "Adjustment factors": "None"
            },
            "measures": "[Odds Ratio]",
            "outcomes": "[0.29]"
        },
        {
            "subject": {
                "HIV-1 acquisition": "retained significance",
                "Odds Ratio (AOR)": "0.37",
                "Confidence Interval (CI)": "0.15-0.90",
                "P-value": "0.029",
                "Bonferroni corrected P-value (PBonf)": "0.464",
                "Dataset": "Perinatal HIV-1 acquisition",
                "Adjustment factors": "Birthweight and FCGR2C genotypes"
            },
            "measures": "[Adjusted Odds Ratio]",
            "outcomes": "[0.37]"
        },
        {
            "subject": {
                "FCGR2C gene copy": "single copy",
                "Association": "reduced odds of HIV-1 acquisition",
                "Dataset": "Perinatal HIV-1 acquisition"
            },
            "measures": "[Association]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "FCGR2C gene copy": "\u22653 copies",
                "Odds Ratio (OR)": "0.99",
                "Confidence Interval (CI)": "0.63-1.57",
                "P-value": "0.978",
                "Bonferroni corrected P-value (PBonf)": "0.275",
                "Dataset": "Perinatal HIV-1 acquisition",
                "Adjustment factors": "None"
            },
            "measures": "[Odds Ratio]",
            "outcomes": "[0.99]"
        },
        {
            "subject": {
                "FCGR2C gene copy": "\u22653 copies",
                "Odds Ratio (AOR)": "0.74",
                "Confidence Interval (CI)": "0.43-1.27",
                "P-value": "0.275",
                "Bonferroni corrected P-value (PBonf)": "0.275",
                "Dataset": "Perinatal HIV-1 acquisition",
                "Adjustment factors": "Birthweight and FCGR2C genotypes"
            },
            "measures": "[Adjusted Odds Ratio]",
            "outcomes": "[0.74]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "Feeding Mode": "Exclusive breast feeding",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "2.45%",
                "Unadjusted HR": "1.35 [0.52-3.49]",
                "Unadjusted HR p-value": "0.54"
            },
            "measures": "[0.52-3.49]",
            "outcomes": [
                "[Unadjusted Hazard Ratio]",
                "[1.35]"
            ]
        },
        {
            "subject": {
                "Feeding Mode": "Exclusive breast feeding",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "2.45%",
                "Adjusted HR": "1.16 [0.44-3.08]",
                "Adjusted HR p-value": "0.76"
            },
            "measures": "[0.44-3.08]",
            "outcomes": [
                "[Adjusted Hazard Ratio]",
                "[1.16]"
            ]
        },
        {
            "subject": {
                "Feeding Mode": "Mixed feeding",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "13.33%",
                "Unadjusted HR": "0.31 [0.04-2.42]",
                "Unadjusted HR p-value": "0.26"
            },
            "measures": "[0.04-2.42]",
            "outcomes": [
                "[Unadjusted Hazard Ratio]",
                "[0.31]"
            ]
        },
        {
            "subject": {
                "Feeding Mode": "Mixed feeding",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "13.33%",
                "Adjusted HR": "0.44 [0.053-3.74]",
                "Adjusted HR p-value": "0.45"
            },
            "measures": "[0.053-3.74]",
            "outcomes": [
                "[Adjusted Hazard Ratio]",
                "[0.44]"
            ]
        },
        {
            "subject": {
                "Feeding Mode": "Exclusive replacement feeding",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "Ref",
                "Unadjusted HR": "Ref",
                "Unadjusted HR p-value": "Ref"
            },
            "measures": "[Unadjusted Hazard Ratio]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "HIV Status": "Positive",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "Ref",
                "Unadjusted HR": "0.31 [0.11-0.90]",
                "Unadjusted HR p-value": "0.032"
            },
            "measures": "[0.11-0.90]",
            "outcomes": [
                "[Unadjusted Hazard Ratio]",
                "[0.31]"
            ]
        },
        {
            "subject": {
                "HIV Status": "Positive",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "Ref",
                "Adjusted HR": "0.30 [0.08-1.11]",
                "Adjusted HR p-value": "0.071"
            },
            "measures": "[0.08-1.11]",
            "outcomes": [
                "[Adjusted Hazard Ratio]",
                "[0.30]"
            ]
        },
        {
            "subject": {
                "Birth weight": ">=2500 g",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "Ref",
                "Unadjusted HR": "0.88 [0.34-2.28]",
                "Unadjusted HR p-value": "0.80"
            },
            "measures": "[0.34-2.28]",
            "outcomes": [
                "[Unadjusted Hazard Ratio]",
                "[0.88]"
            ]
        },
        {
            "subject": {
                "Birth weight": ">=2500 g",
                "Study Population": "HIV exposed infants",
                "Hospital": "Essos hospital center",
                "Program": "PMTCT",
                "Survival Period": "24 months",
                "Mortality Rate": "Ref",
                "Adjusted HR": "0.93 [0.21-4.12]",
                "Adjusted HR p-value": "0.92"
            },
            "measures": "[0.21-4.12]",
            "outcomes": [
                "[Adjusted Hazard Ratio]",
                "[0.93]"
            ]
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "Covariate": "Length of follow-up",
                "Estimate": "\u22120.0138",
                "Standard Error": "0.0666",
                "Confidence Interval": "(\u22120.1322\u20130.1046)",
                "Analysis Type": "Meta-regression",
                "Dependent Variable": "Study",
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[\u22120.0138]"
        },
        {
            "subject": {
                "Covariate": "Median CD4 count",
                "Estimate": "\u22120.0034",
                "Standard Error": "0.0066",
                "Confidence Interval": "(\u22120.0150\u20130.0079)",
                "Analysis Type": "Meta-regression",
                "Dependent Variable": "Study",
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[\u22120.0034]"
        },
        {
            "subject": {
                "Covariate": "Median age",
                "Estimate": "0.0415",
                "Standard Error": "0.0503",
                "Confidence Interval": "(\u22120.1013\u20130.0755)",
                "Analysis Type": "Meta-regression",
                "Dependent Variable": "Study",
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[0.0415]"
        },
        {
            "subject": {
                "Covariate": "Year of publication",
                "Estimate": "0.0637",
                "Standard Error": "0.0815",
                "Confidence Interval": "(\u22120.1736\u20130.0980)",
                "Analysis Type": "Meta-regression",
                "Dependent Variable": "Study",
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[0.0637]"
        },
        {
            "subject": {
                "Covariate": "Proportion of female",
                "Estimate": "\u22120.5305",
                "Standard Error": "1.4575",
                "Confidence Interval": "(\u22123.6792\u20132.6183)",
                "Analysis Type": "Meta-regression",
                "Dependent Variable": "Study",
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Estimate]",
            "outcomes": "[\u22120.5305]"
        },
        {
            "subject": {
                "Method": "Meta regression",
                "Objective": "Determine whether there is a significant association between independent variables in the form of study versus the dependent variable"
            },
            "measures": "[Method]",
            "outcomes": ""
        },
        {
            "subject": {
                "Covariates": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Covariates]",
            "outcomes": ""
        },
        {
            "subject": {
                "Dependent Variable": "Study"
            },
            "measures": "[Dependent Variable]",
            "outcomes": ""
        },
        {
            "subject": {
                "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
            },
            "measures": "[Independent Variables]",
            "outcomes": ""
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "Cohort": "studied cohort",
                "Table": "Table 2",
                "Context": "Distribution of KIR alleles",
                "Metric": "Frequency of KIR alleles",
                "KIR Genotypes": "Cent"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "Cohort": "studied cohort",
                "Table": "Table 2",
                "Context": "Distribution of KIR alleles",
                "Metric": "Frequency of KIR alleles",
                "KIR Genotypes": "Tel"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL1",
                "Value": "97%",
                "Metric": "Frequency",
                "Outcome": "966"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL3",
                "Value": "72%",
                "Metric": "Frequency",
                "Outcome": "719"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL4",
                "Value": "100%",
                "Metric": "Frequency",
                "Outcome": "993"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL5",
                "Value": "55%",
                "Metric": "Frequency",
                "Outcome": "547"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL2*004",
                "Value": "3%",
                "Metric": "Frequency",
                "Outcome": "31"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DL2*001/2/3/5",
                "Value": "55%",
                "Metric": "Frequency",
                "Outcome": "544"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DP1",
                "Value": "97%",
                "Metric": "Frequency",
                "Outcome": "964"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DS1",
                "Value": "55%",
                "Metric": "Frequency",
                "Outcome": "548"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DS2",
                "Value": "59%",
                "Metric": "Frequency",
                "Outcome": "581"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DS3",
                "Value": "40%",
                "Metric": "Frequency",
                "Outcome": "401"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DS4",
                "Value": "100%",
                "Metric": "Frequency",
                "Outcome": "993"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR2DS5",
                "Value": "28%",
                "Metric": "Frequency",
                "Outcome": "281"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR3DL1",
                "Value": "94%",
                "Metric": "Frequency",
                "Outcome": "929"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR3DL2",
                "Value": "100%",
                "Metric": "Frequency",
                "Outcome": "993"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR3DL3",
                "Value": "100%",
                "Metric": "Frequency",
                "Outcome": "993"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        },
        {
            "subject": {
                "KIR": "KIR3DS1",
                "Value": "36%",
                "Metric": "Frequency",
                "Outcome": "354"
            },
            "measures": "[N, % Positive]",
            "outcomes": ""
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "Group": "Overall",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "4/1956 (0\u00b720%)",
                "Events per total PY in TDF-FTC group": "36/1942 (1\u00b785%)",
                "HR (hazard ratio)": "0\u00b712 (0\u00b705\u20130\u00b731)",
                "p value": "<0\u00b70001",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b712]"
        },
        {
            "subject": {
                "Group": "Age",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "HR (hazard ratio)": ".",
                "p value": "0\u00b753",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "Age <25 years",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "3/866 (0\u00b735%)",
                "Events per total PY in TDF-FTC group": "20/851 (2\u00b734%)",
                "HR (hazard ratio)": "0\u00b717 (0\u00b705\u20130\u00b754)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b717]"
        },
        {
            "subject": {
                "Group": "Age \u226525 years",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "1/1090 (0\u00b709%)",
                "Events per total PY in TDF-FTC group": "16/1091 (1\u00b747%)",
                "HR (hazard ratio)": "0\u00b709 (0\u00b702\u20130\u00b749)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b709]"
        },
        {
            "subject": {
                "Group": "Contraceptive method",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "HR (hazard ratio)": ".",
                "p value": "0\u00b787",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "Contraceptive method DMPA",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "3/1009 (0\u00b730%)",
                "Events per total PY in TDF-FTC group": "21/1000 (2\u00b710%)",
                "HR (hazard ratio)": "0\u00b716 (0\u00b705\u20130\u00b753)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b716]"
        },
        {
            "subject": {
                "Group": "Contraceptive method NET-EN",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "1/175 (0\u00b757%)",
                "Events per total PY in TDF-FTC group": "6/182 (3\u00b730%)",
                "HR (hazard ratio)": "0\u00b722 (0\u00b703\u20131\u00b748)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b722]"
        },
        {
            "subject": {
                "Group": "Contraceptive method Implant",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "0",
                "Events per total PY in TDF-FTC group": "8/607 (1\u00b732%)",
                "HR (hazard ratio)": "0\u00b706 (0\u00b700\u20131\u00b716)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b706]"
        },
        {
            "subject": {
                "Group": "Contraceptive method Other",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "0",
                "Events per total PY in TDF-FTC group": "1/152 (0\u00b766%)",
                "HR (hazard ratio)": "0\u00b732 (0\u00b701\u20139\u00b789)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b732]"
        },
        {
            "subject": {
                "Group": "Body-mass index \u226430 kg/m<sup>2</sup>",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "4/1389 (0\u00b729%)",
                "Events per total PY in TDF-FTC group": "27/1447 (1\u00b787%)",
                "HR (hazard ratio)": "0\u00b716 (0\u00b706\u20130\u00b745)",
                "p value": "0\u00b747",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b716]"
        },
        {
            "subject": {
                "Group": "Body-mass index >30 kg/m<sup>2</sup>",
                "Intervention": "Cabotegravir",
                "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                "Events per total PY in cabotegravir group": "0",
                "Events per total PY in TDF-FTC group": "9/495 (1\u00b782%)",
                "HR (hazard ratio)": "0\u00b705 (0\u00b700\u20130\u00b796)",
                "p value": ".",
                "Endpoint": "HIV incidence",
                "Analysis": "ITT",
                "Dataset": "40 HIV infections"
            },
            "measures": "[HR]",
            "outcomes": "[0\u00b705]"
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes"
            },
            "measures": "[Incident HIV infections]",
            "outcomes": "[11, 6]"
        },
        {
            "subject": {
                "Group": "TDF/FTC",
                "No. subjects": "2693",
                "PYFU": "4386",
                "Incident HIV infections": "11",
                "Incidence rate (per 100 PYFU)": "0.251",
                "Rate ratio (95% CI)": "REF",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes",
                "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "Credibility limit": "lower 2.5%"
            },
            "measures": "[Incident HIV infections]",
            "outcomes": "[11]"
        },
        {
            "subject": {
                "Group": "TDF/FTC",
                "No. subjects": "2693",
                "PYFU": "4386",
                "Incident HIV infections": "11",
                "Incidence rate (per 100 PYFU)": "0.251",
                "Rate ratio (95% CI)": "REF",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes",
                "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "Credibility limit": "lower 2.5%"
            },
            "measures": "[Incidence rate (per 100 PYFU)]",
            "outcomes": "[0.251]"
        },
        {
            "subject": {
                "Group": "TAF/FTC",
                "No. subjects": "2694",
                "PYFU": "4370",
                "Incident HIV infections": "6",
                "Incidence rate (per 100 PYFU)": "0.137",
                "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes",
                "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "Credibility limit": "lower 2.5%"
            },
            "measures": "[Incident HIV infections]",
            "outcomes": "[6]"
        },
        {
            "subject": {
                "Group": "TAF/FTC",
                "No. subjects": "2694",
                "PYFU": "4370",
                "Incident HIV infections": "6",
                "Incidence rate (per 100 PYFU)": "0.137",
                "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes",
                "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "Credibility limit": "lower 2.5%"
            },
            "measures": "[Incidence rate (per 100 PYFU)]",
            "outcomes": "[0.137]"
        },
        {
            "subject": {
                "Caption": "DISCOVER trial: primary outcome analysis",
                "Trial": "DISCOVER",
                "Primary outcome analysis": "Yes"
            },
            "measures": "[Incident HIV infections]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Footnote": "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)",
                "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                "Credibility limit": "lower 2.5%"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[Rate per 100 person-year]",
            "outcomes": "[3.02]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[Rate per 100 person-year CI lower bound]",
            "outcomes": "[2.53]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[Rate per 100 person-year CI upper bound]",
            "outcomes": "[3.61]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio]",
            "outcomes": "[Current]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[p-value]",
            "outcomes": "[< 0.001]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[Cutoffs]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[3.02]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[95% CI]",
            "outcomes": "[2.53, 3.61]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        },
        {
            "subject": {
                "Endpoint": "Composite endpoint",
                "n": "692",
                "No. of event": "123",
                "Person-year of follow-up": "4071",
                "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                "CD4/CD8 ratio": "Current",
                "p-value": "< 0.001"
            },
            "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category range]",
            "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "HIV-1 Genotype": "Total",
                "Patients": "no. (%), 2845 (100.0)",
                "CD4+ median (IQR)": "160 (49\u2013310)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            }
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF01_AE",
                "Patients": "no. (%), 1687 (59.3)",
                "CD4+ median (IQR)": "111 (31\u2013279)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient]",
            "outcomes": "[0]"
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF07_BC",
                "Patients": "no. (%), 254 (8.9)",
                "CD4+ median (IQR)": "250 (156\u2013377)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient]",
            "outcomes": [
                "[139]",
                "[95% CI]",
                "[(117\u2013161)]",
                "[P-value]",
                "[<0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF08_BC",
                "Patients": "no. (%), 728 (25.6)",
                "CD4+ median (IQR)": "205 (108\u2013327)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient]",
            "outcomes": [
                "[94]",
                "[95% CI]",
                "[(73\u2013115)]",
                "[P-value]",
                "[<0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "Others",
                "Patients": "no. (%), 176 (6.2)",
                "CD4+ median (IQR)": "198 (89\u2013355)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient]",
            "outcomes": [
                "[87]",
                "[95% CI]",
                "[(46\u2013128)]",
                "[P-value]",
                "[<0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF01_AE",
                "Patients": "no. (%), 1687 (59.3)",
                "CD4+ median (IQR)": "111 (31\u2013279)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Adjusted Coefficient]",
            "outcomes": [
                "[0]",
                "[95% CI]",
                "[(\u2013)]",
                "[P-value]",
                "[(\u2013)]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF07_BC",
                "Patients": "no. (%), 254 (8.9)",
                "CD4+ median (IQR)": "250 (156\u2013377)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Adjusted Coefficient]",
            "outcomes": [
                "[113]",
                "[95% CI]",
                "[(86\u2013140)]",
                "[P-value]",
                "[<0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF08_BC",
                "Patients": "no. (%), 728 (25.6)",
                "CD4+ median (IQR)": "205 (108\u2013327)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Adjusted Coefficient]",
            "outcomes": [
                "[80]",
                "[95% CI]",
                "[(65\u201395)]",
                "[P-value]",
                "[<0.001]"
            ]
        },
        {
            "subject": {
                "HIV-1 Genotype": "Others",
                "Patients": "no. (%), 176 (6.2)",
                "CD4+ median (IQR)": "198 (89\u2013355)",
                "Dataset": "Newly diagnosed HIV patients",
                "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
            },
            "measures": "[Adjusted Coefficient]",
            "outcomes": [
                "[72]",
                "[95% CI]",
                "[(37\u2013107)]",
                "[P-value]",
                "[<0.001]"
            ]
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "HIV detection visit"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[381]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M3"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[114]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M6"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[73]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M9"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[43]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M12"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[26]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M15"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[17]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "HIV detection visit"
            },
            "measures": "[CD4 count]",
            "outcomes": "[382]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M3"
            },
            "measures": "[CD4 count]",
            "outcomes": "[115]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M6"
            },
            "measures": "[CD4 count]",
            "outcomes": "[73]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M9"
            },
            "measures": "[CD4 count]",
            "outcomes": "[44]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M12"
            },
            "measures": "[CD4 count]",
            "outcomes": "[26]"
        },
        {
            "subject": {
                "Analysis group": "As-randomized",
                "Total participants": "382",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M15"
            },
            "measures": "[CD4 count]",
            "outcomes": "[17]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "HIV detection visit"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[330]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M3"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[99]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M6"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[65]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M9"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[40]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M12"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M15"
            },
            "measures": "[HIV VL count]",
            "outcomes": "[14]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "HIV detection visit"
            },
            "measures": "[CD4 count]",
            "outcomes": "[331]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M3"
            },
            "measures": "[CD4 count]",
            "outcomes": "[99]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M6"
            },
            "measures": "[CD4 count]",
            "outcomes": "[64]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M9"
            },
            "measures": "[CD4 count]",
            "outcomes": "[40]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M12"
            },
            "measures": "[CD4 count]",
            "outcomes": "[25]"
        },
        {
            "subject": {
                "Analysis group": "Continuous use",
                "Total participants": "331",
                "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                "Dataset": "HIV Seroconverter Data",
                "Timepoint": "M15"
            },
            "measures": "[CD4 count]",
            "outcomes": "[14]"
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "HIV Exposure": "All children",
                "No.": "1024",
                "CMV Viremia": "No. (%), 314 (30.7)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 59 (5.8)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[30.7]"
        },
        {
            "subject": {
                "HIV Exposure": "All children",
                "No.": "1024",
                "CMV Viremia": "No. (%), 314 (30.7)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 59 (5.8)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia \u2264 1000 IU/mL Percentage]",
            "outcomes": "[5.8]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV unexposed",
                "No.": "872",
                "CMV Viremia": "No. (%), 253 (29.0)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 45 (5.2)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection"
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[29.0]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV exposed",
                "No.": "118",
                "CMV Viremia": "No. (%), 45 (38.1)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 10 (8.5)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[38.1]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV exposed uninfected",
                "No.": "97",
                "CMV Viremia": "No. (%), 36 (37.1)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[37.1]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV infected",
                "No.": "15",
                "CMV Viremia": "No. (%), 6 (40.0)",
                "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                "Dataset": "Hospitalized children",
                "Stratification": "HIV exposure or infection",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[40.0]"
        },
        {
            "subject": {
                "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
            },
            "measures": "[CMV Viremia Percentage]",
            "outcomes": "[31.0]"
        },
        {
            "subject": {
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[None]",
            "outcomes": "[None]"
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "executive function",
                "Gender": "Females",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": "[1.3]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "executive function",
                "Gender": "Males",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": [
                "[3.5]",
                "[Confidence Interval]",
                "[1.5\u20135.5]",
                "[p-value]",
                "[0.008]"
            ]
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Females",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": "[0.9]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Males",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": [
                "[1.8]",
                "[Confidence Interval]",
                "[1.2\u20132.9]",
                "[p-value]",
                "[0.01]"
            ]
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Hispanics",
                "Race/Ethnicity": "Hispanics",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": "[2.6]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "African American",
                "Race/Ethnicity": "African American",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[Odds Ratio]",
            "outcomes": [
                "[3.1]",
                "[Confidence Interval]",
                "[2.3\u20133.5]",
                "[p-value]",
                "[0.01]"
            ]
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Hispanics",
                "Race/Ethnicity": "Hispanics",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "African American",
                "Race/Ethnicity": "African American",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Hispanics",
                "Race/Ethnicity": "Hispanics",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.32]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "African American",
                "Race/Ethnicity": "African American",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.72]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Females",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.013]"
        },
        {
            "subject": {
                "Gene": "DRD2",
                "SNP": "rs6277",
                "Phenotype": "cognitive flexibility",
                "Gender": "Males",
                "Race/Ethnicity": "Not specified",
                "Alcohol use": "Not specified",
                "Hardy\u2013Weinberg equilibrium": "Yes"
            },
            "measures": "[p-value interaction]",
            "outcomes": "[0.35]"
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[12]",
                "[Percentage of Total G3+ Events]",
                "[30.0]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[15]",
                "[Percentage of Total G3+ Events]",
                "[25.0]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Respiratory and thoracic disorders",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[7]",
                "[Percentage of Total G3+ Events]",
                "[17.5]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Respiratory and thoracic disorders",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[13]",
                "[Percentage of Total G3+ Events]",
                "[21.7]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Blood and lymphatic disorders",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[6]",
                "[Percentage of Total G3+ Events]",
                "[15.0]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Blood and lymphatic disorders",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[10]",
                "[Percentage of Total G3+ Events]",
                "[16.7]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Infections and infestations",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[3]",
                "[Percentage of Total G3+ Events]",
                "[7.5]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Infections and infestations",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[5]",
                "[Percentage of Total G3+ Events]",
                "[8.3]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Metabolism and nutrition disorders",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[3]",
                "[Percentage of Total G3+ Events]",
                "[7.5]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Metabolism and nutrition disorders",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[4]",
                "[Percentage of Total G3+ Events]",
                "[6.7]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Other",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[9]",
                "[Percentage of Total G3+ Events]",
                "[17.5]"
            ]
        },
        {
            "subject": {
                "Adverse Event SOC": "Other",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[13]",
                "[Percentage of Total G3+ Events]",
                "[16.7]"
            ]
        },
        {
            "subject": {
                "Total Number of Grade 3 or 4 Adverse Events": "",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[20]",
                "[Percentage of Total G3+ Events]",
                "[47.6]"
            ]
        },
        {
            "subject": {
                "Total Number of Grade 3 or 4 Adverse Events": "",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[34]",
                "[Percentage of Total G3+ Events]",
                "[15.5]"
            ]
        },
        {
            "subject": {
                "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                "HIV Status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[11]",
                "[Percentage of Total G3+ Events]",
                "[26.2]"
            ]
        },
        {
            "subject": {
                "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                "HIV Status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Enrollment Phase": "Yes",
                "Grade": "3 or 4"
            },
            "measures": "[Number of Events]",
            "outcomes": [
                "[14]",
                "[Percentage of Total G3+ Events]",
                "[6.4]"
            ]
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Cancer",
                "Number of deaths": "7 (7%)",
                "Dataset": "Individuals living with HIV",
                "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[7]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Other diseases",
                "Number of deaths": "10 (8%)",
                "Dataset": "Individuals living with HIV",
                "Definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[10]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "CVD",
                "Number of deaths": "12 (9%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[12]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Hepatic/liver-related",
                "Number of deaths": "34 (24%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[34]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "External death",
                "Number of deaths": "78 (55%)",
                "Dataset": "Individuals living with HIV",
                "Definition": "Sudden death, including accident, overdose, and suicide"
            },
            "measures": "[Number of deaths]",
            "outcomes": "[78]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Opportunistic",
                "Number of deaths": "8 (3%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[8]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Other diseases",
                "Number of deaths": "241 (96%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[241]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "Cancer",
                "Number of deaths": "2 (1%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "Death category": "Death category of individuals living with HIV",
                "Cause": "AIDS-Related Death (ARD)",
                "Number of deaths": "8 (3%)",
                "Dataset": "Individuals living with HIV",
                "Definition": ""
            },
            "measures": "[Number of deaths]",
            "outcomes": "[8]"
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "Before access",
                "Number of infections/person-years": "133/2860",
                "Incidence": "4\u00b765%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Incidence]",
            "outcomes": "[4\u00b765]"
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "Before access",
                "Number of infections/person-years": "133/2860",
                "Incidence": "4\u00b765%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            }
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "After access",
                "Number of infections/person-years": "12/556",
                "Incidence": "2\u00b716%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Incidence]",
            "outcomes": "[2\u00b716]"
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "After access",
                "Number of infections/person-years": "12/556",
                "Incidence": "2\u00b716%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            }
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "Before access",
                "Number of infections/person-years": "46/919",
                "Incidence": "5\u00b700%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Incidence]",
            "outcomes": "[5\u00b700]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "Before access",
                "Number of infections/person-years": "46/919",
                "Incidence": "5\u00b700%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            }
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "After access",
                "Number of infections/person-years": "11/481",
                "Incidence": "2\u00b729%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Incidence]",
            "outcomes": "[2\u00b729]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "After access",
                "Number of infections/person-years": "11/481",
                "Incidence": "2\u00b729%",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            }
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "Before access",
                "Adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b781)",
                "p value": "0\u00b70085",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Adjusted incidence rate ratio (95% CI)]",
            "outcomes": "[0\u00b745 (0\u00b725-0\u00b781)]"
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "Before access",
                "p value": "0\u00b70085",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[p value]",
            "outcomes": "[0\u00b70085]"
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "After access",
                "Adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                "p value": "0\u00b70085",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Adjusted incidence rate ratio (95% CI)]",
            "outcomes": "[0\u00b745 (0\u00b725-0\u00b782)]"
        },
        {
            "subject": {
                "Context": "Including study visits with on-site PrEP access",
                "Condition": "After access",
                "p value": "0\u00b70085",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[p value]",
            "outcomes": "[0\u00b70085]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "Before access",
                "Adjusted incidence rate ratio (95% CI)": "0\u00b744 (0\u00b723-0\u00b785)",
                "p value": "0\u00b7012",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Adjusted incidence rate ratio (95% CI)]",
            "outcomes": "[0\u00b744 (0\u00b723-0\u00b785)]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "Before access",
                "p value": "0\u00b7012",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[p value]",
            "outcomes": "[0\u00b7012]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "After access",
                "Adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                "p value": "0\u00b7012",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[Adjusted incidence rate ratio (95% CI)]",
            "outcomes": "[0\u00b743 (0\u00b722-0\u00b783)]"
        },
        {
            "subject": {
                "Context": "180 days before versus 180 days after on-site PrEP access",
                "Condition": "After access",
                "p value": "0\u00b7012",
                "Caption": "Effect of on-site PrEP access on HIV incidence",
                "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
            },
            "measures": "[p value]",
            "outcomes": "[0\u00b7012]"
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "PrEP status": "Overall",
                "HIV infections": "No./total No. of individuals, 91/13 861",
                "Total follow-up": "person-years, 26 210",
                "Incidence (95% CI)": "per 100 person-years, 0.35 (0.28-0.43)",
                "Exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "PrEP status": "Linked but not prescribed PrEP",
                "HIV infections": "No./total No. of individuals, 36/3013",
                "Total follow-up": "person-years, 4119",
                "Incidence (95% CI)": "per 100 person-years, 0.87 (0.63-1.21)"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[0.87]"
        },
        {
            "subject": {
                "PrEP status": "Prescribed PrEP but did not initiate",
                "HIV infections": "No./total No. of individuals, 13/811",
                "Total follow-up": "person-years, 1226",
                "Incidence (95% CI)": "per 100 person-years, 1.06 (0.62-1.83)"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[1.06]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued but reinitiated PrEP",
                "HIV infections": "No./total No. of individuals, 4/1082",
                "Total follow-up": "person-years, 1420",
                "Incidence (95% CI)": "per 100 person-years, 0.28 (0.11-0.75)"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[0.28]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued and did not reinitiate PrEP",
                "HIV infections": "No./total No. of individuals, 38/2108",
                "Total follow-up": "person-years, 2973",
                "Incidence (95% CI)": "per 100 person-years, 1.28 (0.93-1.76)"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[1.28]"
        },
        {
            "subject": {
                "PrEP status": "Persistent on PrEP",
                "HIV infections": "No./total No. of individuals, 0/5367",
                "Total follow-up": "person-years, 9139",
                "Incidence (95% CI)": "per 100 person-years, 0.00 (0.00-0.04)"
            },
            "measures": "[Incidence Rate]",
            "outcomes": "[0.00]"
        },
        {
            "subject": {
                "Citation": "Excluding patients who were diagnosed at linkage",
                "HIV incidence rate": "0.35 (95% CI, 0.28-0.43) new infections per 100 person-years"
            },
            "measures": "[HIV Incidence Rate]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "Citation": "among those not prescribed PrEP",
                "HIV incidence rate": "0.87 (95% CI, 0.63-1.21) new infections per 100 person-years"
            },
            "measures": "[HIV Incidence Rate]",
            "outcomes": "[0.87]"
        },
        {
            "subject": {
                "Citation": "among those prescribed but not initiated",
                "HIV incidence rate": "1.06 (95% CI, 0.62-1.83) new infections per 100 person-years"
            },
            "measures": "[HIV Incidence Rate]",
            "outcomes": "[1.06]"
        },
        {
            "subject": {
                "Citation": "among those who discontinued and did not reinitiate PrEP",
                "HIV incidence rate": "1.28 (95% CI, 0.93-1.76) new infections per 100 person-years"
            },
            "measures": "[HIV Incidence Rate]",
            "outcomes": "[1.28]"
        },
        {
            "subject": {
                "Footnote": "a",
                "Exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[Exclusion Criteria]",
            "outcomes": "[Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage]"
        },
        {
            "subject": {
                "Footnote": "b",
                "PrEP status": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up"
            },
            "measures": "[PrEP Status]",
            "outcomes": "[Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up]"
        },
        {
            "subject": {
                "Footnote": "c",
                "CI": "One-sided 97.5% upper CI"
            },
            "measures": "[CI]",
            "outcomes": "[One-sided 97.5% upper CI]"
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "Gene": "ISG15",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.29",
                "95% Confidence Interval": "0.11\u20130.81",
                "p-value": "0.0091"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.29]"
        },
        {
            "subject": {
                "Gene": "IFI6",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.18",
                "95% Confidence Interval": "0.037\u20130.86",
                "p-value": "0.014"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.18]"
        },
        {
            "subject": {
                "Gene": "IFI44L",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.55",
                "95% Confidence Interval": "0.27\u20131.1",
                "p-value": "0.083"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.55]"
        },
        {
            "subject": {
                "Gene": "IFI44",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.23",
                "95% Confidence Interval": "0.047\u20131.2",
                "p-value": "0.045"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.23]"
        },
        {
            "subject": {
                "Gene": "IFIT1",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.37",
                "95% Confidence Interval": "0.12\u20131.1",
                "p-value": "0.054"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.37]"
        },
        {
            "subject": {
                "Gene": "OAS3",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.52",
                "95% Confidence Interval": "0.22\u20131.3",
                "p-value": "0.15"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.52]"
        },
        {
            "subject": {
                "Gene": "XAF1",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.3",
                "95% Confidence Interval": "0.1\u20130.92",
                "p-value": "0.027"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.3]"
        },
        {
            "subject": {
                "Gene": "TRIM25",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.074",
                "95% Confidence Interval": "0.0068\u20130.8",
                "p-value": "0.023"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.074]"
        },
        {
            "subject": {
                "Gene": "CMPK2",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.23",
                "95% Confidence Interval": "0.037\u20131.5",
                "p-value": "0.074"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.23]"
        },
        {
            "subject": {
                "Gene": "RSAD2",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.2",
                "95% Confidence Interval": "0.041\u20130.99",
                "p-value": "0.032"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.2]"
        },
        {
            "subject": {
                "Gene": "EIF2AK2",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.54",
                "95% Confidence Interval": "0.12\u20132.4",
                "p-value": "0.42"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.54]"
        },
        {
            "subject": {
                "Gene": "USP18",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.23",
                "95% Confidence Interval": "0.062\u20130.84",
                "p-value": "0.022"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.23]"
        },
        {
            "subject": {
                "Gene": "HERC6",
                "Analysis Type": "Univariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Hazard Ratio": "0.16",
                "95% Confidence Interval": "0.019\u20131.3",
                "p-value": "0.057"
            },
            "measures": "[Hazard Ratio]",
            "outcomes": "[0.16]"
        },
        {
            "subject": {
                "Analysis Type": "Multivariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "LASSO": "Used to eliminate genes with zero coefficients"
            },
            "measures": "[LASSO]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Gene": "ISG15",
                "Analysis Type": "Multivariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Correlation": "-0.41"
            },
            "measures": "[Correlation]",
            "outcomes": "[-0.41]"
        },
        {
            "subject": {
                "Gene": "TRIM25",
                "Analysis Type": "Multivariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Correlation": "-0.32"
            },
            "measures": "[Correlation]",
            "outcomes": "[-0.32]"
        },
        {
            "subject": {
                "Gene": "XAF1",
                "Analysis Type": "Multivariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Correlation": "-0.06"
            },
            "measures": "[Correlation]",
            "outcomes": "[-0.06]"
        },
        {
            "subject": {
                "Gene": "USP18",
                "Analysis Type": "Multivariable Cox Regression",
                "Hub Gene Source": "WGCNA",
                "Module": "Salmon Module 1",
                "Correlation": "-0.14"
            },
            "measures": "[Correlation]",
            "outcomes": "[-0.14]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "Population": "Intention-to-treat population",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "Intention-to-treat population",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "Modified MRC grade: Grade I",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "22/99",
                "No. of deaths (Placebo)": "28/97",
                "Hazard ratio": "0.72",
                "Confidence interval": "[0.41, 1.25]",
                "P-value": "0.24",
                "Test for proportional hazards": "0.15",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.41, 1.25]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.72]"
            ]
        },
        {
            "subject": {
                "Population": "Modified MRC grade: Grade II",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "60/125",
                "No. of deaths (Placebo)": "68/126",
                "Hazard ratio": "0.82",
                "Confidence interval": "[0.58, 1.16]",
                "P-value": "0.27",
                "Test for proportional hazards": "0.57",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.58, 1.16]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.82]"
            ]
        },
        {
            "subject": {
                "Population": "Modified MRC grade: Grade III",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "34/39",
                "No. of deaths (Placebo)": "30/34",
                "Hazard ratio": "1.11",
                "Confidence interval": "[0.70, 1.77]",
                "P-value": "0.65",
                "Test for proportional hazards": "0.89",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.70, 1.77]",
            "outcomes": [
                "[Hazard ratio]",
                "[1.11]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[Hazard ratio]",
                "[0.85]"
            ]
        },
        {
            "subject": {
                "Population": "All",
                "Treatment": "Dexamethasone vs. Placebo",
                "No. of deaths (Dexamethasone)": "116/263",
                "No. of deaths (Placebo)": "126/257",
                "Hazard ratio": "0.85",
                "Confidence interval": "[0.66, 1.10]",
                "P-value": "0.22",
                "Test for proportional hazards": "0.36",
                "Endpoint": "Death from any cause over the first 12 months after randomization",
                "Analysis method": "Cox proportional hazards regression model",
                "Kaplan-Meier transformation": "Time transformation"
            },
            "measures": "[0.66, 1.10]",
            "outcomes": [
                "[P-value]",
                "[0.22]"
            ]
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "Group": "Participants without HIV",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Incidence rate unit": "cases/1000 PY",
                "Incidence rate 95% CI": "54.7\u201389.0",
                "HR": "1.00",
                "HR 95% CI": "Reference",
                "Dataset size": "2144 participants at risk"
            },
            "measures": "[Unadjusted incidence rate]",
            "outcomes": "[69.8]"
        },
        {
            "subject": {
                "Group": "PLWH on non-TLD ART",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Incidence rate unit": "cases/1000 PY",
                "Incidence rate 95% CI": "69.8\u201385.2",
                "HR": "1.13",
                "HR 95% CI": "0.79\u20131.63",
                "Dataset size": "2144 participants at risk"
            },
            "measures": "[Unadjusted incidence rate]",
            "outcomes": "[77.1]"
        },
        {
            "subject": {
                "Group": "PLWH on TLD",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Incidence rate unit": "cases/1000 PY",
                "Incidence rate 95% CI": "54.0\u201399.6",
                "HR": "1.77",
                "HR 95% CI": "1.22\u20132.55",
                "Dataset size": "2144 participants at risk"
            },
            "measures": "[Unadjusted incidence rate]",
            "outcomes": "[73.3]"
        },
        {
            "subject": {
                "Group": "PLWH, ART na\u00efve",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Incidence rate unit": "cases/1000 PY",
                "Incidence rate 95% CI": "24.1\u201359.1",
                "HR": "0.43",
                "HR 95% CI": "0.27\u20130.70",
                "Dataset size": "2144 participants at risk"
            },
            "measures": "[Unadjusted incidence rate]",
            "outcomes": "[37.7]"
        },
        {
            "subject": {
                "Group": "All participants",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants": "2144",
                "Number of participants with BMI \u226525 kg/m\u00b2": "516",
                "Percentage of participants with BMI \u226525 kg/m\u00b2": "24.1%"
            },
            "measures": "[Number of participants with BMI \u226525 kg/m\u00b2]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants without HIV": "2144",
                "Number of participants with HIV": "0",
                "Percentage of participants with HIV": "0%"
            },
            "measures": "[Number of participants with HIV]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants on non-TLD ART": "0",
                "Number of participants on TLD": "0",
                "Number of participants on ART na\u00efve": "0"
            },
            "measures": "[Number of participants on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants without HIV and on non-TLD ART": "0",
                "Number of participants without HIV and on TLD": "0",
                "Number of participants without HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants without HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        },
        {
            "subject": {
                "Group": "HIV and ART status",
                "Condition": "BMI \u226525 kg/m\u00b2",
                "Number of participants with HIV and on non-TLD ART": "0",
                "Number of participants with HIV and on TLD": "0",
                "Number of participants with HIV and on ART na\u00efve": "0"
            },
            "measures": "[Number of participants with HIV and on ART]",
            "outcomes": ""
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "Characteristic": "Total number",
                "N": "200",
                "Clustered": "N = 59",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Characteristic": "Odds ratio",
                "95% CI": "Provided",
                "P-value": "Provided",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Age": "15 and younger",
                "Total number": "69",
                "Clustered": "22",
                "Odds ratio": "1.0",
                "95% CI": "0.36\u20131.89",
                "P-value": "0.67",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.67]"
        },
        {
            "subject": {
                "Age": "16",
                "Total number": "46",
                "Clustered": "13",
                "Odds ratio": "0.84",
                "95% CI": "0.36\u20131.89",
                "P-value": "0.67",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.67]"
        },
        {
            "subject": {
                "Age": "17+",
                "Total number": "85",
                "Clustered": "24",
                "Odds ratio": "0.87",
                "95% CI": "0.43\u20131.76",
                "P-value": "0.69",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.69]"
        },
        {
            "subject": {
                "School grade": "8\u20139",
                "Total number": "90",
                "Clustered": "30",
                "Odds ratio": "1.0",
                "95% CI": "Provided",
                "P-value": "\u2026",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "School grade": "10\u201312",
                "Total number": "110",
                "Clustered": "29",
                "Odds ratio": "0.8",
                "95% CI": "0.43\u20131.52",
                "P-value": "0.5",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.5]"
        },
        {
            "subject": {
                "Household income": "<999",
                "Total number": "61",
                "Clustered": "22",
                "Odds ratio": "1.0",
                "95% CI": "Provided",
                "P-value": "\u2026",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Household income": "10,000\u201399,000",
                "Total number": "112",
                "Clustered": "27",
                "Odds ratio": "0.56",
                "95% CI": "0.29\u20131.11",
                "P-value": "0.1",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.1]"
        },
        {
            "subject": {
                "Household income": ">100,000",
                "Total number": "27",
                "Clustered": "10",
                "Odds ratio": "1.04",
                "95% CI": "0.39\u20132.65",
                "P-value": "0.93",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.93]"
        },
        {
            "subject": {
                "CD4 cell count": ">500",
                "Total number": "92",
                "Clustered": "30",
                "Odds ratio": "1.0",
                "95% CI": "Provided",
                "P-value": "\u2026",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "CD4 cell count": "\u2264500",
                "Total number": "75",
                "Clustered": "19",
                "Odds ratio": "0.70",
                "95% CI": "0.35\u20131.37",
                "P-value": "0.31",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.31]"
        },
        {
            "subject": {
                "CD4 cell count": "\u2264250",
                "Total number": "15",
                "Clustered": "4",
                "Odds ratio": "0.75",
                "95% CI": "0.2\u20132.4",
                "P-value": "0.65",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.65]"
        },
        {
            "subject": {
                "Major drug resistance mutation": "No",
                "Total number": "180",
                "Clustered": "55",
                "Odds ratio": "1.0",
                "95% CI": "Provided",
                "P-value": "\u2026",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "Major drug resistance mutation": "Yes",
                "Total number": "20",
                "Clustered": "4",
                "Odds ratio": "0.57",
                "95% CI": "0.16\u20131.63",
                "P-value": "0.33",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[0.33]"
        },
        {
            "subject": {
                "HSV-2 infection": "No",
                "Total number": "90",
                "Clustered": "25",
                "Odds ratio": "1.0",
                "95% CI": "Provided",
                "P-value": "\u2026",
                "Genetic distance threshold": "4.5%",
                "Study participants": "200 HIV-infected",
                "Context": "Associations between demographic and epidemiological characteristics",
                "Footnote": "Pregnancy history was not available for 29 women",
                "Abbreviation": "ref: reference"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ]
}